Ng SY, Lee AYW. Traumatic brain injuries: pathophysiology and potential therapeutic targets. Front Cell Neurosci. 2019;13:528.
Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007;99:4–9.
Khellaf A, Khan DZ, Helmy A. Recent advances in traumatic brain injury. J Neurol. 2019;266:2878–89.
Cai L, Gong Q, Qi L, Xu T, Suo Q, Li X, Wang W, Jing Y, Yang D, Xu Z, et al. ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway. Cell Commun Signal. 2022;20:56.
Abdul-Muneer P, Chandra N, Haorah J. Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol. 2015;51:966–79.
Readnower RD, Chavko M, Adeeb S, Conroy MD, Pauly JR, McCarron RM, et al. Increase in blood–brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res. 2010;88:3530–9.
Blennow K, Brody DL, Kochanek PM, Levin H, McKee A, Ribbers GM, et al. Traumatic brain injuries. Nat Rev Dis Primers. 2016;2:1–19.
Maas AI, Menon DK, Manley GT, Abrams M, Åkerlund C, Andelic N, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21:1004–60.
Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13.
Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023;8:217.
Ma X, Zhao Y, Liang X-J. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44:1114–22.
Kim Y, Kim J, An JM, Park C-K, Kim D. All-nontoxic fluorescent probe for biothiols and its clinical applications for real-time glioblastoma visualization. ACS Sens. 2023;8:1723–32.
Kim J, Um H, Kim NH, Kim D. Potential Alzheimer’s disease therapeutic nano-platform: discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles. Bioact Mater. 2023;24:497–506.
Kang RH, Jang J-E, Huh E, Kang SJ, Ahn D-R, Kang JS, et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma. Nanoscale Horiz. 2020;5:1213–25.
Brahmi M, Bakirhan NK. Innovations in traumatic brain injury diagnostics: electrochemical impedance spectroscopy leading the way. J Appl Electrochem. 2024;55:1–17.
Dhull A, Zhang Z, Sharma R, Dar AI, Rani A, Wei J, Gopalakrishnan S, Ghannam A, Hahn V, Pulukuri AJ, et al. Discovery of 2-deoxy glucose surfaced mixed layer dendrimer: a smart neuron targeted systemic drug delivery system for brain diseases. Theranostics. 2024;14:3221–45.
McHugh EA, Liopo AV, Mendoza K, Robertson CS, Wu G, Wang Z, Chen W, Beckham JL, Derry PJ, Kent TA, Tour JM. Oxidized activated charcoal nanozymes: synthesis, and optimization for in vitro and in vivo bioactivity for traumatic brain injury. Adv Mater. 2024;36:e2211239.
Robbins EM, Wong B, Pwint MY, Salavatian S, Mahajan A, Cui XT. Improving sensitivity and longevity of in vivo glutamate sensors with electrodeposited nanopt. ACS Appl Mater Interfaces. 2024;16:40570–80.
Rubby MF, Fonder C, Uchayash S, Liang X, Sakaguchi DS, Que L. Assessment of the behaviors of an in vitro brain model on-chip under shockwave impacts. ACS Appl Mater Interfaces. 2024;16:33246–58.
Kim Y, An JM, Kim J, Chowdhury T, Yu HJ, Kim K-M, Kang H, Park C-K, Joung JF, Park S. Pyridine-NBD: A homocysteine-selective fluorescent probe for glioblastoma (GBM) diagnosis based on a blood test. Anal Chim Acta. 2022;1202:339678.
Singha S, Kim D, Rao AS, Wang T, Kim KH, Lee K-H, et al. Two-photon probes based on arylsulfonyl azides: fluorescence detection and imaging of biothiols. Dyes Pigments. 2013;99:308–15.
Zuidema JM, Kumeria T, Kim D, Kang J, Wang J, Hollett G, Zhang X, Roberts DS, Chan N, Dowling C. Oriented nanofibrous polymer scaffolds containing protein-loaded porous silicon generated by spray nebulization. Adv Mater. 2018;30:1706785.
Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, Petroni G, Lujan S, Pridgeon J, Barber J. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367:2471–81.
Guan B, Anderson DB, Chen L, Feng S, Zhou H. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990–2019: a systematic analysis for the global burden of disease study 2019. BMJ Open. 2023;13:e075049.
James SL, Theadom A, Ellenbogen RG, Bannick MS, Montjoy-Venning W, Lucchesi LR, et al. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:56–87.
Stein MB, Kessler RC, Heeringa SG, Jain S, Campbell-Sills L, Colpe LJ, et al. Prospective longitudinal evaluation of the effect of deployment-acquired traumatic brain injury on posttraumatic stress and related disorders: results from the army study to assess risk and resilience in servicemembers (Army STARRS). Am J Psychiatry. 2015;172:1101–11.
Johnson BD. Sports-related subconcussive head trauma. Concussions Athletics: Brain Behav. 2021;249–69.
Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44:2–10.
Fernandes FAO. Biomechanical analysis of helmeted head impacts: novel materials and geometries. Universidade de Aveiro (Portugal); 2019.
Johnson WD, Griswold DP. Traumatic brain injury: a global challenge. Lancet Neurol. 2017;16:949–50.
Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9:231–6.
Harvey LA, Close JC. Traumatic brain injury in older adults: characteristics, causes and consequences. Injury. 2012;43:1821–6.
Thompson HJ, McCormick WC, Kagan SH. Traumatic brain injury in older adults: epidemiology, outcomes, and future implications. J Am Geriatr Soc. 2006;54:1590–5.
Toth L, Czigler A, Horvath P, Kornyei B, Szarka N, Schwarcz A, Ungvari Z, Buki A, Toth P. Traumatic brain injury-induced cerebral microbleeds in the elderly. Geroscience. 2021;43:125–36.
Reger MA, Brenner LA, du Pont A. Traumatic brain injury and veteran mortality after the war in Afghanistan. JAMA Netw Open. 2022;5:e2148158-2148158.
Stein DG, Geddes RI, Sribnick EA. Recent developments in clinical trials for the treatment of traumatic brain injury. Handb Clin Neurol. 2015;127:433–51.
DePalma RG, Hoffman SW. Combat blast related traumatic brain injury (TBI): decade of recognition; promise of progress. Behav Brain Res. 2018;340:102–5.
Duckworth JL, Grimes J, Ling GS. Pathophysiology of battlefield associated traumatic brain injury. Pathophysiology. 2013;20:23–30.
Marklund N. Blast-Induced Brain Injury. Management of Severe Traumatic Brain Injury: Evidence, Tricks, and Pitfalls 2020:109–113.
Aravind A, Ravula AR, Chandra N, Pfister BJ. Behavioral deficits in animal models of blast traumatic brain injury. Front Neurol. 2020;11:990.
Bugay V, Bozdemir E, Vigil FA, Chun SH, Holstein DM, Elliott WR, et al. A mouse model of repetitive blast traumatic brain injury reveals post-trauma seizures and increased neuronal excitability. J Neurotrauma. 2020;37:248–61.
Tomura S, Seno S, Kawauchi S, Miyazaki H, Sato S, Kobayashi Y, et al. A novel mouse model of mild traumatic brain injury using laser-induced shock waves. Neurosci Lett. 2020;721:134827.
Kandell RM, Kudryashev JA, Kwon EJ. Targeting the extracellular matrix in traumatic brain injury increases signal generation from an activity-based nanosensor. ACS Nano. 2021;15:20504–16.
Kandell RM, Wu JR, Kwon EJ. Reprogramming clots for in vivo chemical targeting in traumatic brain injury. Adv Mater. 2024;2301738.
Nikolian VC, Dekker SE, Bambakidis T, Higgins GA, Dennahy IS, Georgoff PE, et al. Improvement of blood-brain barrier integrity in traumatic brain injury and hemorrhagic shock following treatment with valproic acid and fresh frozen plasma. Crit Care Med. 2018;46:e59-66.
Salehi A, Zhang JH, Obenaus A. Response of the cerebral vasculature following traumatic brain injury. J Cereb Blood Flow Metab. 2017;37:2320–39.
Winkler EA, Minter D, Yue JK, Manley GT. Cerebral edema in traumatic brain injury: pathophysiology and prospective therapeutic targets. Neurosurg Clin N Am. 2016;27:473–88.
Maas AI, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16:987–1048.
Meyfroidt G, Bouzat P, Casaer MP, Chesnut R, Hamada SR, Helbok R, Hutchinson P, Maas AI, Manley G, Menon DK. Management of moderate to severe traumatic brain injury: an update for the intensivist. Intensive Care Med. 2022;48:649–66.
van Erp IA, Michailidou I, van Essen TA, van der Jagt M, Moojen W, Peul WC, Baas F, Fluiter K. Tackling neuroinflammation after traumatic brain injury: complement Inhibition as a therapy for secondary injury. Neurotherapeutics. 2023;20:284–303.
Zhang X, Huang X, Hang D, Jin J, Li S, Zhu Y, et al. Targeting pyroptosis with nanoparticles to alleviate neuroinflammatory for preventing secondary damage following traumatic brain injury. Sci Adv. 2024;10:eadj4260.
Bharadwaj VN, Nguyen DT, Kodibagkar VD, Stabenfeldt SE. Nanoparticle-based therapeutics for brain injury. Adv Healthc Mater. 2018;7:1700668.
Mohammed FS, Omay SB, Sheth KN, Zhou J. Nanoparticle-based drug delivery for the treatment of traumatic brain injury. Expert Opin Drug Deliv. 2023;20:55–73.
Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol. 2005;63:301–6.
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5(6):506–19.
Saatman KE, Creed J, Raghupathi R. Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics. 2010;7:31–42.
Cagmat EB, Guingab-Cagmat JD, Vakulenko AV, Hayes RL, Anagli J. Potential use of calpain inhibitors as brain injury therapy. 2015.
Kudryashev JA, Waggoner LE, Leng HT, Mininni NH, Kwon EJ. An activity-based nanosensor for traumatic brain injury. ACS Sens. 2020;5:686–92.
Baudry M, Luo YL, Bi X. Calpain-2 inhibitors as therapy for traumatic brain injury. Neurotherapeutics. 2023;20:1592–602.
Schoch KM, Von Reyn CR, Bian J, Telling GC, Meaney DF, Saatman KE. Brain injury-induced proteolysis is reduced in a novel calpastatin‐overexpressing transgenic mouse. J Neurochem. 2013;125:909–20.
Bains M, Cebak JE, Gilmer LK, Barnes CC, Thompson SN, Geddes JW, et al. Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. J Neurochem. 2013;125:125–32.
Andriessen TM, Jacobs B, Vos PE. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med. 2010;14:2381–92.
Czogalla A, Sikorski A. Spectrin and calpain: a ‘target’and a ‘sniper’in the pathology of neuronal cells. Cell Mol Life Sci. 2005;62:1913–24.
Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D, Smith DH. Blood biomarkers for traumatic brain injury: a quantitative assessment of diagnostic and prognostic accuracy. Front Neurol. 2019;10:446.
Hamakubo T, Kannagi R, Murachi T, Matus A. Distribution of calpains I and II in rat brain. J Neurosci. 1986;6:3103–11.
Siman R, Giovannone N, Hanten G, Wilde EA, McCauley SR, Hunter JV, Li X, Levin HS, Smith DH. Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients. Front Neurol. 2013;4:190.
Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18:165–80.
Yan X-X, Jeromin A. Spectrin breakdown products (SBDPs) as potential biomarkers for neurodegenerative diseases. Curr Transl Geriatr Exp Gerontol Rep. 2012;1:85–93.
Madias MI, Stessman LN, Warlof SJ, Kudryashev JA, Kwon EJ. Spatial measurement and inhibition of calpain activity in traumatic brain injury with an activity-based nanotheranostic platform. ACS Nano. 2024;18:25565–76.
Han Z, Han Y, Huang X, Ma H, Zhang X, Song J, Dong J, Li S, Yu R, Liu H. A novel targeted nanoparticle for traumatic brain injury treatment: combined effect of ROS depletion and calcium overload Inhibition. Adv Healthc Mater. 2022;11:2102256.
Shohami E, Kohen R. The role of reactive oxygen species in the pathogenesis of traumatic brain injury. Oxidative Stress Free Radical Damage Neurol 2011; 99–118.
Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med. 1999;26:463–71.
Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17:871–90.
Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol. 1997;31:53–64.
Pandya JD, Musyaju S, Modi HR, Cao Y, Flerlage WJ, Huynh L, Kociuba B, Visavadiya NP, Kobeissy F, Wang K. Comprehensive evaluation of mitochondrial redox profile, calcium dynamics, membrane integrity and apoptosis markers in a preclinical model of severe penetrating traumatic brain injury. Free Radic Biol Med. 2023;198:44–58.
Yang Y, Li Z, Fan X, Jiang C, Wang J, Rastegar-Kashkooli Y, Wang TJ, Wang J, Wang M, Cheng N, et al. Nanozymes: potential therapies for reactive oxygen species overproduction and inflammation in ischemic stroke and traumatic brain injury. ACS Nano. 2024;18:16450–67. https://doi.org/10.1021/acsnano.4c03425
Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6:393–403.
Bharadwaj VN, Lifshitz J, Adelson PD, Kodibagkar VD, Stabenfeldt SE. Temporal assessment of nanoparticle accumulation after experimental brain injury: effect of particle size. Sci Rep. 2016;6:29988.
Boyd BJ, Galle A, Daglas M, Rosenfeld JV, Medcalf R. Traumatic brain injury opens blood–brain barrier to stealth liposomes via an enhanced permeability and retention (EPR)-like effect. J Drug Target. 2015;23:847–53.
Waggoner LE, Kang J, Zuidema JM, Vijayakumar S, Hurtado AA, Sailor MJ, et al. Porous silicon nanoparticles targeted to the extracellular matrix for therapeutic protein delivery in traumatic brain injury. Bioconjug Chem. 2022;33:1685–97.
Waggoner LE, Madias MI, Hurtado AA, Kwon EJ. Pharmacokinetic analysis of peptide-modified nanoparticles with engineered physicochemical properties in a mouse model of traumatic brain injury. AAPS J. 2021;23:100.
Yoo D, Magsam AW, Kelly AM, Stayton PS, Kievit FM, Convertine AJ. Core-cross-linked nanoparticles reduce neuroinflammation and improve outcome in a mouse model of traumatic brain injury. ACS Nano. 2017;11:8600–11.
Cernak I, Savic J, Ignjatovic D, Jevtic M. Blast injury from explosive munitions. J Trauma Acute Care Surg. 1999;47:96–103.
Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods. 1991;39:253–62.
Duhaime A-C. Large animal models of traumatic injury to the immature brain. Dev Neurosci. 2006;28:380–7.
Duhaime A-C, Margulies SS, Durham SR, O’Rourke MM, Golden JA, Marwaha S, et al. Maturation-dependent response of the piglet brain to scaled cortical impact. J Neurosurg. 2000;93:455–62.
Dutchke J, Anderson R, Sandoz B, Finnie J, Manavis J, Nishimoto T, Morris T, Wells A, Turner R, Vink R. A biomechanical model of traumatic contusional injury produced by controlled cerebrocortical indentation in sheep. In IRCOBI Conference Proceedings. 2016: 354–368.
King C, Robinson T, Dixon CE, Rao GR, Larnard D, Nemoto CEM. Brain temperature profiles during epidural cooling with the chillerpad in a monkey model of traumatic brain injury. J Neurotrauma. 2010;27:1895–903.
Leung LY, Larimore Z, Holmes L, Cartagena C, Mountney A, Deng-Bryant Y, Schmid K, Shear D, Tortella F. The WRAIR projectile concussive impact model of mild traumatic brain injury: re-design, testing and preclinical validation. Ann Biomed Eng. 2014;42:1618–30.
Lighthall JW. Controlled cortical impact: a new experimental brain injury model. J Neurotrauma. 1988;5:1–15.
Namjoshi DR, Cheng WH, McInnes KA, Martens KM, Carr M, Wilkinson A, et al. Merging pathology with biomechanics using CHIMERA (Closed-Head impact model of engineered rotational Acceleration): a novel, surgery-free model of traumatic brain injury. Mol Neurodegener. 2014;9:1–18.
Romine J, Gao X, Chen J. Controlled cortical impact model for traumatic brain injury. J Visualized Experiments: JoVE 2014;51781.
Williams AJ, Hartings JA, Lu X-CM, Rolli ML, Dave JR, Tortella FC. Characterization of a new rat model of penetrating ballistic brain injury. J Neurotrauma. 2005;22:313–31.
Laurer HL, Lenzlinger PM, McIntosh TK. Models of traumatic brain injury. Eur J Trauma. 2000;26:95–110.
Lisi I, Moro F, Mazzone E, Marklund N, Pischiutta F, Kobeissy F, Mao X, Corrigan F, Helmy A, Nasrallah F. Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury. Brain. 2025;148:1062–80.
Petersen A, Soderstrom M, Saha B, Sharma P. Animal models of traumatic brain injury: a review of pathophysiology to biomarkers and treatments. Exp Brain Res. 2021;239:2939–50.
Adelson PD, Ragheb J, Muizelaar JP, Kanev P, Brockmeyer D, Beers SR, Brown SD, Cassidy LD, Chang Y, Levin H. Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children. Neurosurgery. 2005;56:740–54.
Adelson PD, Wisniewski SR, Beca J, Brown SD, Bell M, Muizelaar JP, et al. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol. 2013;12:546–53.
Beca J, McSharry B, Erickson S, Yung M, Schibler A, Slater A, et al. Hypothermia for traumatic brain injury in children—a phase II randomized controlled trial. Crit Care Med. 2015;43:1458–66.
Collaborators CT. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC crash trial): randomised placebo-controlled trial. Lancet. 2004;364:1321–8.
Robertson CS, McCarthy JJ, Miller ER, Levin H, McCauley SR, Swank PR. Phase II clinical trial of atorvastatin in mild traumatic brain injury. J Neurotrauma. 2017;34:1394–401.
Skolnick BE, Maas AI, Narayan RK, Van Der Hoop RG, MacAllister T, Ward JD, et al. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med. 2014;371:2467–76.
Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA. Ander DS: protect: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49:391–402. e392.
Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371:2457–66.
Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma. 2015;32:1834–48.
Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728–41.
Nowak M, Helgeson ME, Mitragotri S. Delivery of nanoparticles and macromolecules across the blood–brain barrier. Adv Ther. 2020;3:1900073.
Diaz MD, Kandell RM, Wu JR, Chen A, Christman KL, Kwon EJ. Infusible extracellular matrix biomaterial promotes vascular integrity and modulates the inflammatory response in acute traumatic brain injury. Adv Healthc Mater. 2023;12:2300782.
Kudryashev JA, Madias MI, Kandell RM, Lin QX, Kwon EJ. An activity-Based nanosensor for Minimally‐Invasive measurement of protease activity in traumatic brain injury. Adv Funct Mater. 2023;33:2300218.
Lagraoui M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC. Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun. 2017;61:96–109.
Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB. Transcranial amelioration of inflammation and cell death after brain injury. Nature. 2014;505:223–8.
Sharma R, Kambhampati SP, Zhang Z, Sharma A, Chen S, Duh EI, et al. Dendrimer mediated targeted delivery of sinomenine for the treatment of acute neuroinflammation in traumatic brain injury. J Controlled Release. 2020;323:361–75.
Zhu Y, Wang H, Fang J, Dai W, Zhou J, Wang X, Zhou M. SS-31 provides neuroprotection by reversing mitochondrial dysfunction after traumatic brain injury. Oxidative Medicine and Cellular Longevity 2018, 2018:4783602.
Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She Z-G, Kotamraju VR, Ranscht B. A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. Nat Commun. 2016;7:11980.
Ruoslahti E. Molecular ZIP codes in targeted drug delivery. Proc Natl Acad Sci U S A. 2022;119:e2200183119.
Mu X, He H, Wang J, Long W, Li Q, Liu H, Gao Y, Ouyang L, Ren Q, Sun S, et al. Carbogenic nanozyme with ultrahigh reactive nitrogen species selectivity for traumatic brain injury. Nano Lett. 2019;19:4527–34.
Waggoner LE, Miyasaki KF, Kwon EJ. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury. Biomater Sci. 2023;11:4238–53.
Han S, Yoo W, Carton O, Joo J, Kwon EJ. Pegylated multimeric RNA nanoparticles for siRNA delivery in traumatic brain injury. Small. 2025;21:2405806.
Kandell RM, Wu JR, Kwon EJ. Reprograming clots for in vivo chemical targeting in traumatic brain injury. Adv Mater. 2024;36:2301738.
